- All sections
- C - Chemistry; metallurgy
- C07D - Heterocyclic compounds
- C07D 209/40 - Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
Patent holdings for IPC class C07D 209/40
Total number of patents in this class: 258
10-year publication summary
|
16
|
20
|
21
|
18
|
15
|
16
|
20
|
19
|
16
|
0
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Achillion Pharmaceuticals, Inc. | 168 |
24 |
| IFM Due, Inc. | 37 |
15 |
| Novartis Pharma AG | 85 |
13 |
| City of Hope | 960 |
7 |
| Cornell University | 3202 |
6 |
| Novita Pharmaceuticals, Inc. | 21 |
6 |
| Vertex Pharmaceuticals Incorporated | 1568 |
5 |
| Purdue Research Foundation | 3477 |
5 |
| National and Kapodistrian University of Athens | 34 |
4 |
| VALO Health, Inc. | 168 |
4 |
| F. Hoffmann-La Roche AG | 7942 |
3 |
| BioCryst Pharmaceuticals, Inc. | 176 |
3 |
| China Pharmaceutical University | 274 |
3 |
| Council of Scientific & Industrial Research | 1409 |
3 |
| Epizyme, Inc. | 386 |
3 |
| Ligand Pharmaceuticals Incorporated | 120 |
3 |
| Taipei Medical University | 176 |
3 |
| Oncternal Therapeutics, Inc. | 49 |
3 |
| Glaxosmithkline LLC | 539 |
2 |
| Boehringer Ingelheim International GmbH | 4754 |
2 |
| Other owners | 141 |